Valeant Pays $13M To End Diabetes Drug Royalty Claims
Valeant Pharmaceuticals International Inc. will pay $13 million to biotechnology company PDL BioPharma Inc. to settle a lawsuit alleging that Valeant owes more than $20 million in unpaid royalties for sales...To view the full article, register now.
Already a subscriber? Click here to view full article